InsidersTradesSigma
Track the Personalis, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Personalis, Inc. has published 87 public disclosures. Market capitalisation: €1.8bn. The latest transaction was disclosed on 15 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: West John Stephen. All data is free.
87
Insider Decl.
n/a
Thresholds
€438,283
1 ops.
Buy Volume
€10m
42 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Personalis, Inc. Buy (bullish), based on 4 analysts. Average price target: US$15.44.
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,512 of 29,064 companies
20.5
score / 100
Value23
Quality18
FCF yld-4.4%
Earn yld-4.5%
EV/EBITDA·
ROE-50%
Gross mgn23%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 July 2026
Declarations87 total
100,000 shares@ US$15.030.096% mcap100.0% of flowCommonSEC144:0001950047-26-007108
100,000 shares@ US$2.440.016% mcap12.6% of flowCommon StockSEC:0001779787-26-000003:0
100,000 shares@ US$15.150.097% mcap78.5% of flowCommon StockSEC:0001779787-26-000003:1
100,000 shares@ US$1.610.011% mcap9.6% of flowCommon StockSEC:0001449535-26-000006:0
100,000 shares@ US$15.080.098% mcap90.4% of flowCommon StockSEC:0001449535-26-000006:1
100,000 sharesCommon StockSEC:0001449535-26-000004:0
100,000 sharesCommon StockSEC:0001449535-26-000004:1
40,000 shares@ US$10.780.029% mcap100.0% of flowCommonSEC144:0001950047-26-005657
6,250 shares0Common StockSEC:0001231845-26-000001:0
6,250 shares0Common StockSEC:0001008891-26-000001:0
6,250 shares0Common StockSEC:0001501545-26-000001:0
6,250 shares0Common StockSEC:0001471716-26-000001:0
6,250 shares0Common StockSEC:0001065168-26-000001:0
6,250 shares0Common StockSEC:0001243399-26-000001:0
3,440 shares@ US$3.290.0008% mcap1.4% of flowCommon StockSEC:0001209191-22-038443:0
1,565 shares@ US$3.290.0004% mcap2.0% of flowCommon StockSEC:0001209191-22-038445:0
6,818 shares@ US$3.241.3% of flowCommon StockSEC:0001209191-22-037962:0
6,818 shares@ US$3.244.6% of flowCommon StockSEC:0001209191-22-037952:0
1,832 shares@ US$3.2414.6% of flowCommon StockSEC:0001209191-22-037973:0
4,187 shares@ US$3.593.1% of flowCommon StockSEC:0001209191-22-034616:0
421 shares@ US$3.590.1% of flowCommon StockSEC:0001209191-22-034599:0
10,770 shares0Common StockSEC:0001209191-22-030769:0
10,770 shares0Common StockSEC:0001209191-22-030756:0
10,770 shares0Common StockSEC:0001209191-22-030776:0
10,770 shares0Common StockSEC:0001209191-22-030753:0
25 of 87 declarations
关于 Personalis, Inc.
Personalis, Inc. 是一家总部位于美国的精准基因组学公司，在纳斯达克（美国）上市，股票代码为 PSNL。该公司由斯坦福大学的下一代测序领导团队于2011年创立，通过专注于癌症和免疫反应的深度分子分析，在精准肿瘤学领域建立了差异化地位。Personalis 目前总部位于加利福尼亚州弗里蒙特，在那里运营着一个经 CLIA 认证、CAP 认可的实验室。其商业模式位于临床基因组学、生物制药服务和生物标志物驱动的肿瘤学的交叉点，使其成为一个专业参与者，而非广谱诊断公司。（[investors.personalis.com](https://investors.personalis.com/?utm_source=openai)） 该公司的核心特许经营权是 NeXT 平台，旨在从肿瘤样本中生成高度全面的基因组和免疫学数据。Personalis 的产品和服务组合包括用于全面肿瘤分析的 NeXT Dx、用于肿瘤和微环境特征分析的 ImmunoID NeXT，以及用于超灵敏检测微小残留病灶和癌症复发的 NeXT Personal MRD。除了这些临床和转化产品，Personalis 还为生物制药客户提供临床试验、伴随诊断开发和研究项目的测序和生物标志物服务。这种组合使公司既能接触到研究阶段的需求，也能接触到日益重要的临床诊断市场。（[investors.personalis.com](https://investors.personalis.com/news-releases/news-release-details/personalis-inc-announces-launch-next-dxtm-test-comprehensive?utm_source=openai)） 从竞争角度来看，Personalis 在一个拥挤且快速发展的市场中运营，其中包括分子诊断公司、NGS 平台提供商和肿瘤检测专家。其主要区别在于其基因组覆盖的广度、肿瘤和免疫系统信息的整合，以及与药物开发商合作的长期记录。该公司强调了与 Moderna、Merck、Tempus 和 VA Million Veterans Program 的合作关系，这既突显了其科学平台的质量，也突显了战略合作伙伴关系对其增长战略的重要性。同时，这些关系也凸显了客户集中度和执行风险。（[investors.personalis.com](https://investors.personalis.com/news-releases/news-release-details/personalis-reports-fourth-quarter-and-full-year-2025-results-and?utm_source=openai)） 近期发展表明 Personalis 正在从一个研究赋能的故事日益转向一个临床商业执行的故事。在其最新的公开更新中，该公司强调了临床检测量的强劲增长、乳腺癌复发监测和 I-III 期 NSCLC 的里程碑式医保覆盖胜利，以及与 Tempus 扩大协议以在结直肠癌中推广 NeXT Personal Dx。管理层还宣布了首席执行官的退休和过渡，创始人 John West 在 DNA 测序领域长期职业生涯后卸任。对于投资者而言，PSNL 仍然是一个高风险、催化剂驱动的纳斯达克股票：其上涨取决于报销、临床采用以及将其科学差异化转化为可持续收入增长的能力。（[investors.personalis.com](https://investors.personalis.com/node/8851/pdf?utm_source=openai)）
